Ardelyx (ARDX) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$450.9M

Revenue (quarter)

$120.9M

Revenue growth (year over year)

+23.77%

Gross profit (trailing twelve months)

$425.5M

Gross margin

94.37%

Net income (trailing twelve months)

−$55.7M

Net income (quarter)

−$16.7M

Net income growth (year over year)

+12.36%

Net margin

−12.35%

Return on equity

−38.61%

EPS (trailing twelve months)

−$0.23

Book value per share

$0.60

P/E (trailing twelve months)

—

Price to book

5.41

Debt to assets

74.12%

Payout ratio

—

Dividend yield

—

Company profile

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

• Is Ardelyx (ARDX) profitable?

  No. Ardelyx reported a net loss of $55.7M over the trailing twelve months.

• How much revenue does Ardelyx (ARDX) make?

  Ardelyx generated $450.9M in revenue over the trailing twelve months, up 23.77% year over year.

• How do I buy stock in Ardelyx (ARDX)?

  ARDX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.